ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 102 filers reported holding ASCENDIS PHARMA A/S in Q2 2018. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,178,334 | -4.1% | 247,526 | -8.6% | 0.00% | 0.0% |
| Q2 2023 | $24,159,171 | +1027.1% | 270,691 | +1254.1% | 0.00% | – |
| Q1 2023 | $2,143,435 | -41.1% | 19,991 | -32.9% | 0.00% | – |
| Q4 2022 | $3,640,451 | +71.0% | 29,808 | +44.6% | 0.00% | – |
| Q3 2022 | $2,129,000 | +27.5% | 20,616 | +14.7% | 0.00% | – |
| Q2 2022 | $1,670,000 | -9.6% | 17,980 | +14.2% | 0.00% | – |
| Q1 2022 | $1,847,000 | +28.4% | 15,743 | +47.1% | 0.00% | – |
| Q4 2021 | $1,439,000 | -40.1% | 10,700 | -29.0% | 0.00% | – |
| Q3 2021 | $2,401,000 | +20.7% | 15,068 | -0.4% | 0.00% | – |
| Q2 2021 | $1,990,000 | +41.5% | 15,122 | +38.6% | 0.00% | – |
| Q1 2021 | $1,406,000 | +39.9% | 10,907 | +81.1% | 0.00% | – |
| Q4 2020 | $1,005,000 | +44.0% | 6,023 | +33.0% | 0.00% | – |
| Q3 2020 | $698,000 | +28.3% | 4,528 | +23.0% | 0.00% | – |
| Q2 2020 | $544,000 | -71.7% | 3,682 | -78.4% | 0.00% | – |
| Q1 2020 | $1,919,000 | +19.1% | 17,040 | +47.1% | 0.00% | – |
| Q4 2019 | $1,611,000 | +7.8% | 11,582 | -25.3% | 0.00% | – |
| Q3 2019 | $1,494,000 | -41.4% | 15,498 | -30.0% | 0.00% | – |
| Q2 2019 | $2,549,000 | +6.7% | 22,135 | +9.1% | 0.00% | – |
| Q1 2019 | $2,388,000 | +163.0% | 20,288 | +39.9% | 0.00% | – |
| Q4 2018 | $908,000 | -76.3% | 14,498 | -73.2% | 0.00% | -100.0% |
| Q3 2018 | $3,835,000 | +81.2% | 54,130 | +70.2% | 0.00% | – |
| Q2 2018 | $2,116,000 | +617.3% | 31,813 | +605.4% | 0.00% | – |
| Q1 2018 | $295,000 | -27.9% | 4,510 | -55.9% | 0.00% | – |
| Q4 2017 | $409,000 | +155.6% | 10,219 | +130.7% | 0.00% | – |
| Q3 2017 | $160,000 | +19.4% | 4,430 | -8.1% | 0.00% | – |
| Q2 2017 | $134,000 | -10.7% | 4,822 | -9.8% | 0.00% | – |
| Q1 2017 | $150,000 | +70.5% | 5,345 | +23.6% | 0.00% | – |
| Q4 2016 | $88,000 | +35.4% | 4,325 | +34.1% | 0.00% | – |
| Q3 2016 | $65,000 | -90.4% | 3,225 | -93.7% | 0.00% | – |
| Q2 2016 | $680,000 | +64.3% | 51,256 | +129.7% | 0.00% | – |
| Q1 2016 | $414,000 | +8.4% | 22,311 | +7.0% | 0.00% | – |
| Q4 2015 | $382,000 | +13.4% | 20,859 | +9.5% | 0.00% | – |
| Q3 2015 | $337,000 | -1.2% | 19,055 | -1.2% | 0.00% | – |
| Q2 2015 | $341,000 | +16.4% | 19,280 | +14.1% | 0.00% | – |
| Q1 2015 | $293,000 | – | 16,892 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |